Trials / Completed
CompletedNCT02762721
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 131 (actual)
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples
Detailed description
This is a non-interventional, observational study of archived human tissue samples; no surgical procedures will be required and no treatment will be provided as part of this study. Approximately 150 archived tissue samples obtained from patients with iCCA or mixed HCC-CCA will be analyzed for somatic alteration status and will include cholangiocarcinoma-specific FGFR2 fusion isoforms.
Conditions
Timeline
- Start date
- 2016-06-06
- Primary completion
- 2017-04-06
- Completion
- 2017-04-06
- First posted
- 2016-05-05
- Last updated
- 2017-06-08
Locations
6 sites across 2 countries: United States, Italy
Source: ClinicalTrials.gov record NCT02762721. Inclusion in this directory is not an endorsement.